Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen shares rise on profit gains

Sales of the biotechnology giant's anemia drugs fell in the second quarter, but higher earnings boosted the stock after hours.

NEW YORK (CNNMoney.com) -- Amgen reported a significant boost to second-quarter earnings Thursday after taking a large acquisition-related charge last year.

Biotech giant Amgen also announced that its experimental cancer drug denosumab met all its goals in a pivotal clinical trial of breast cancer patients.

Shares were gaining as much as 2 percent in after-hours trading on the Nasdaq.

Excluding certain items, Amgen earned $1.12 per share, beating analysts' estimates of $1.07 per share, according to Reuters Estimates.

Minus a $1.1 billion charge related to the company's purchase of cancer drug developer Abgenix last year, Amgen earned $1.05 a share in the second quarter of 2006.

Overall, Amgen saw a net profit of $1.02 billion, or 90 cents per share, compared with $14 million, or 1 cent per share, a year ago.

The world's largest biotechnology company in terms of sales, Amgen reported a revenue gain of 3 percent in the second quarter $3.7 billion, up from $3.6 billion a year ago. Sales of its anemia drugs sank 6 percent.

Amgen's (down $0.79 to $56.38, Charts, Fortune 500) stock is down 17 percent this year, hurt by concerns that its best-selling anemia drug Aranesp is unsafe and overused. This compares to a 4 percent gain by the American Stock Exchange Biotech Index year to date. Top of page